# Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

> **NCT00266318** · PHASE4 · COMPLETED · sponsor: **Beth Israel Medical Center** · enrollment: 40 (—)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Interferon Alfacon-1 and Ribavirin

## Key facts

- **NCT ID:** NCT00266318
- **Lead sponsor:** Beth Israel Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266318, "Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00266318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*